Roche, Exelixis' Tecentriq/Cabometyx combo flunks second PhIII
Roche and Exelixis are reporting a second flop out of a trio of Phase III trials designed to test a combination of their PD-L1 drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
